Bristol Myers Squibb reports Phase 3 trial shows 51% lower progression risk for Zenbexus in multiple myeloma
Bristol Myers Squibb announced that its Phase 3 EXCALIBER‑RRMM study met its primary endpoints, showing that Zenbexus (iberdomide) combined with daratumumab and dexamethasone cut the risk of disease progression or death by 51% versus the standard daratumumab‑bortezomib‑dexamethasone regimen. The median progression‑free survival was 42 months for the Zenbexus regimen compared with 20 months for the comparator. The trial enrolled 800 patients and the data will be presented at the American Society of Hematology meeting in December.
Why it matters
The company says the results could broaden Zenbexus’s market potential beyond its current indication. Investors may see a boost to future sales, although the stock fell 1.41% to $58.86 after the announcement.
Key facts
- 1The EXCALIBER‑RRMM study randomized 800 patients, with 400 receiving Zenbexus + daratumumab + dexamethasone and 400 receiving daratumumab + bortezomib + dexamethasone. gurufocus.com
- 2Median progression‑free survival was 42 months for the Zenbexus regimen versus 20 months for the comparator. gurufocus.com
- 3The hazard ratio for progression or death was 0.49, indicating a 51% risk reduction. gurufocus.com
- 4Median follow‑up was 23 months. gurufocus.com
- 5All‑grade neutropenia occurred in 90.2% of patients on Zenbexus, with Grade 3 in 30.9% and Grade 4 in 53.4%. marketscreener.com
- 6Serious infections were reported in 40% of Zenbexus patients, with fatal infections in 2%. marketscreener.com
Open questions
- Material 1 reports median follow‑up of 23 months, while material 4 cites 16 months.
Summary written by AlphAI from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.